Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients-Reference-Cited by-同舟云学术

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

Published:2022-11-24 Issue:2 Volume:64 Page:478-482
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kutsch Nadine¹,Holmes Emily Eva¹,Robrecht Sandra¹,Schüler Gudrun²,Vehling-Kaiser Ursula³,Decker Thomas⁴,Müller-Hagen Sigrun⁵,Heinisch Karin⁶,Böttcher Sebastian⁷,Ritgen Matthias⁸,Kreuzer Karl-Anton⁹,Stilgenbauer Stephan¹⁰,Fink Anna Maria¹,Fischer Kirsten¹,Eichhorst Barbara¹,Hallek Michael¹,Wendtner Clemens-Martin¹¹

Affiliation:

1. Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University Hospital of Cologne, Cologne, Germany

2. Praxis für Hämatologie und Onkologie Cottbus, Cottbus, Germany

3. BAG MVZ Dr. Vehling-Kaiser GmbH, Landshut, Landshut, Germany

4. Onkologie Ravensburg, Ravensburg, Germany

5. Onkologie und Palliativmedizin Hamburg, Praxis für Hämatologie, Hamburg, Germany

6. Klinikum Lippe Standort Lemgo, Lemgo, Germany

7. Medizinische Klinik III, University Hospital of Rostock, Rostock, Germany

8. Innere Medizin III, University Hospital Schleswig Holstein, Kiel, Germany

9. Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany

10. Division of CLL, Klinik für Innere Medizin III, University Hospital Ulm, Ulm, Germany

11. Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University (LMU), Munich, Germany

Funder

F. Hoffmann-La Roche Ltd.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2148210

Reference14 articles.

1. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

2. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

3. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

4. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

5. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study;Leukemia & Lymphoma;2023-04-16

2. Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?;Leukemia & Lymphoma;2023-03-10